Anzeige
Mehr »
Dienstag, 10.02.2026 - Börsentäglich über 12.000 News
Breaking News: Pacifica meldet neue hochgradige Entdeckung und genau deshalb kann der Markt das nicht ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
224 Leser
Artikel bewerten:
(1)

Ovation Science Inc.: Ovation Science Announces Extended Rights for DermSafe Hand Sanitizer

VANCOUVER, BC / ACCESSWIRE / June 15, 2020 / (CSE:OVAT) - Ovation Science Inc. ("Ovation" or the "Company") is pleased to announce it has signed a revised agreement for additional rights for its DermSafe hand sanitizer (the "License Renewal Agreement") under the terms of the original License Agreement with Skinvisible Pharmaceuticals, Inc., previously announced February 13, 2020. The License Renewal Agreement provides Ovation with immediate additional rights which will assist in the sales and marketing of the product internationally.

The original License Agreement provided Ovation with the exclusive worldwide rights to DermSafe hand sanitizer for an initial period of three years with renewal rights. The License Renewal Agreement extends the License Agreement indefinitely, (subject only to the royalty), for payment in advance of the renewal fee of USD $100,000. In addition to the extension, Ovation will also be transferred the following rights:

  1. Two (2) Health Canada Drug Identification Numbers - 02310589 and 02355558
  2. DermSafe trademark;
  3. DermSafe clinical data; and
  4. The right to patent DermSafe in countries where not currently patented.

"We felt it was important that we expedite our agreement for DermSafe so that Ovation has possession of all of the rights and approvals that are in place but not yet identified under the Ovation name. Shortly all Health Canada records will be updated and Ovation will be identified as the owner of the two Drug Identification Numbers (DINs) as well as being on Health Canada's approval of DermSafe under "Disinfectants and hand sanitizers accepted under COVID-19 interim measure", said Terry Howlett, President of Ovation.

The License Renewal Agreement was approved by Ovation's directors with Terry Howlett and Doreen McMorran abstained from voting to approve the License Renewal Agreement due to their disclosable interest in the transaction contemplated with Skinvisible Pharmaceuticals, Inc. as they are significant shareholders and creditors of Skinvisible and Mr. Howlett is also the President and a director.

For information about Ovation Science products visit https://ovationscience.com/products/.

To learn more about Ovation Science, please visit: www.ovationscience.com

Follow Ovation Science on Twitter: @OvationScience

About Ovation Science Inc.

Ovation Science Inc. is a research and development company that develops topical and transdermal consumer products including DermSafe, all made with patented Invisicare® skin delivery technology. The technology enhances the delivery of ingredients to and through the skin and is protected by patents in eleven countries. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation's management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales. Ovation has offices in Vancouver, BC Canada and Las Vegas, Nevada, USA. Ovation trades on the CSE under the symbol OVAT. Visit our website www.ovationscience.com.

Statements have not been evaluated by the Food and Drug Administration or Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease. Ovation does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Contacts:

INVESTOR RELATIONS:

Sebastian Kunyz: ovat@kincommunications.com Phone: 604-684-6730 or 866-684-6730

FOR BUSINESS DEVELOPMENT & CORPORATE INQUIRIES:

Doreen McMorran: doreen@ovationscience.com Phone: 604.283.0903 ext. 4

SOURCE: Ovation Science Inc.



View source version on accesswire.com:
https://www.accesswire.com/593743/Ovation-Science-Announces-Extended-Rights-for-DermSafe-Hand-Sanitizer

© 2020 ACCESS Newswire
Vorsicht, geheim!
2026 startet mit einem Paukenschlag: Der DAX outperformt den US-Markt, Nachzügler holen auf. Ein erstes Signal, dass der Bullenmarkt an Breite gewinnt. Während viele Anleger weiter auf die großen Tech-Namen setzen, hat sich im Hintergrund längst ein Umschwung vollzogen. Der Fokus verschiebt sich weg von überteuerten KI-Highflyern hin zu soliden Qualitätswerten aus der zweiten Reihe.

Anleger, die jetzt clever agieren, setzen nicht auf das, was war, sondern auf das, was kommt. Unternehmen mit gesunder Bilanz, unterschätztem Potenzial und begrenztem Abwärtsrisiko könnten 2026 zu den großen Gewinnern zählen. Die Gefahr einer schärferen Korrektur bleibt real, gerade für passiv aufgestellte Investoren.

In unserem neuen Spezialreport stellen wir fünf Aktien vor, die genau jetzt das Potenzial für überdurchschnittliche Renditen bieten. Stark, günstig und bislang kaum im Fokus.

Jetzt kostenlosen Report herunterladen – bevor es andere tun!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.